This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by De Mello, W. C Search for Related Content PubMed PubMed Citation Articles by De Mello, W. C Social Bookmarking                         What's this?

Beneficial Effect of Eplerenone on Cardiac Remodelling and Electrical Properties of the Failing Heart

Department of Pharmacology Medical Sciences Campus, UPR, San Juan, PR 00936-5067, USA, wmello{at}rcm.upr.edu

Introduction. The effect of chronic administration of eplerenone on cardiac remodelling and electrical properties was investigated in the failing heart of cardiomyopathic hamsters (TO-2) at five months of age.

Materials and Methods. Two-month-old hamsters were treated with eplerenone (200 mg/kg/day) administered into the chow for a period of three months. Measurements of membrane potential were performed with intracellular microelectrodes connected to a high impedance DC amplifier. The thickness of the ventricular wall as well as the area of fibrosis were measured. To investigate the influence of eplerenone on the electrogenic sodium pump myocytes were isolated from the ventricle and the pump current density was whole cell clamp configuration. measured in voltage clamped cells using the whole cell clamp configuration

Results. The results indicated that: 1) the width of the left and right ventricular wall was significantly reduced; 2) the heart weight/body weight ratio was decreased by 38±2.4% (n=24 P ) (p<0.05); 3) the fibrotic area in the left ventricle (LV) was reduced by 12.6±2% (n=25) (p<0.05); 4) the incidence of cardiac arrhythmias was decreased from 58±3.8% (n=20) in the control to 40±4.1% (n=20) (p<0.05) in animals treated with eplerenone. Moreover, a significant reduction in the dispersion of the QT interval was found with the drug; 5) eplerenone increased the resting potential of ventricular fibres from 64.3±1.5 mV to 73.4±1.4 mV (n=30) (p<0.05), an effect related to the activation of an electrogenic sodium pump. The conduction velocity, in longitudinal direction, was enhanced from 50±2.2 cm/s (n=10) in the controls to 59±2.4 cm/s (n=13) (p<0.05) in animals treated with eplerenone.

Conclusions. Eplerenone reduces cardiac remodelling, the incidence of cardiac arrhythmias and improves impulse propagation, an effect in part related to the antifibrotic effect of the drug but also to the activation of the electrogenic sodium pump.

Key Words: Eplerenone • Electrical properties • Sodium pump • Failing heart

References

• Delcayre C., Swyngedauw B. Molecular mechanisms of myocardial remodelling. The role of aldosterone. J Mol Cell Cardiol 2002;34:1577-84.
• Delcayre C., Heymes C., Milliez P., Swynghedauw B. Trophic effects of aldosterone (De Mello WC, ed.). Renin Angiotensin System and the Heart, London. John Wiley and Sons, 2004;pp161-77.
• Yoshida M., Ma J., Tomita T. et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 2005;11:12-16.[CrossRef][Medline] [Order article via Infotrieve]
• Ramires FJ, Mansur A., Coelho O. et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000;85:1207-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Horisberger JD, Rossier BC Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 1992;19:221-7.[Abstract/Free Full Text]
• Rocha R., Funder JW The pathophysiology of aldosterone in the cardiovascular system. Ann. New York Acad Sci 2002;970:89-100.[Web of Science][Medline] [Order article via Infotrieve]
• Pitt B., Zannad F., Remme WJ et al. for the Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
• Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction and myocardial infarction. New Engl J Med 2003;348:1309-21.[Abstract/Free Full Text]
• Weismand HF, Weinfeldt ML Toward an understanding of the molecular basis of cardiomyopathies. J Am Coll Cardiol 1987;10:1135-8.[Web of Science]
• De Mello WC Renin angiotensin system and cell communication in the failing heart. Hypertension 1996;27:1267-72.[Abstract/Free Full Text]
• De Mello WC, Cherry R., Mannivannan S. Electrophysiologic and morphologic abnormalities in the failing heart; effect of enalapril on the electrical properties. Cardiac Failure 1997;3:53-62.[CrossRef][Medline] [Order article via Infotrieve]
• Powell T., Twist T. A rapid technique for the isolation and purification of adult cardiac muscle cells having respiratory control and a tolerance to calcium. Biochem Biophys Res Commun 1976;72:327-33.[Web of Science][Medline] [Order article via Infotrieve]
• Tanigushi Y., Kokubun S., Noma A., Irisawa H. Spontaneously active cells isolated from the sinoatrial and atrioventricular nodes of the rabbit heart. Jpn J Physiol 1981;31:547-58.[Web of Science][Medline] [Order article via Infotrieve]
• Farquharson CAJ, Struthers AD Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/ angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.[Abstract/Free Full Text]
• Wahed MI, Watanabe K., Ma M. et al. Effect of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodelling in rats with dilated cardiomyopathy. Pharmacology 2005;73:81-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pitt B., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831-8.[Abstract/Free Full Text]
• De Mello WC Heart failure: how important is cellular sequestration? The role of the renin angiotensin aldosterone system. J Mol Cell Cardiol 2004;37:431-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mihailidou AS, Bundsgaard H., Mardini M., Hansen PS, Kjeldsen K., Rasmussen HH Hyperaldosterolemia in rabbits inhibits the cardiac sarcolemmal Na (+)-K(+) pump. Circ Res 2000;86:37-42.[Abstract/Free Full Text]
• Kolla V., Litwak G. Transcriptional regulation of the human N/K ATPase via the humans mineralocorticoid receptor. Mol Cell Biochem 2000;204:35-40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 1, 40-46 (2006)
DOI: 10.3317/jraas.2006.005


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by De Mello, W. C Search for Related Content PubMed PubMed Citation Articles by De Mello, W. C Social Bookmarking                         What's this?